References
- Kirszenbaum M, Djoulah S, Hors J, Prost S, Dausset J, Carosella E D. Polymorphism of HLA-G gene and protein. J Reprod Immunol 1999; 43: 105–109
- Hammer A, Hutter H, Dohr G. HLA class I expression on the materno-fetal interface. Am J Reprod Immunol 1997; 38: 150–157
- Kovats S, Main E K, Librach C, Stubblebine M, Fisher S J, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248: 220–223
- Parham P. Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Am J Reprod Immunol 1995; 34: 10–19
- Rouas-Freiss N, Moreau P, Ferrone S, Carosella E D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 2005; 65: 10139–10144
- Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss E H, Dichgans J, et al. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 2003; 126: 176–185
- Le Friec G, Laupeze B, Fardel O, Sebti Y, Pangault C, Guilloux V, et al. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Human Immunol 2003; 64: 752–761
- Park G M, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004; 313: 606–611
- Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella E D, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196: 266–274
- Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal F A, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510–4515
- Ibrahim E C, Guerra N, Lacombe M J, Angevin E, Chouaib S, Carosella E D, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001; 61: 6838–6845
- Sebti Y, Le Friec G, Pangault C, Gros F, Drenou B, Guilloux V, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003; 64: 1093–1101
- Amiot L, Le Friec G, Sebti Y, Drenou B, Pangault C, Guilloux V, et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 2003; 13: 379–385
- Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006; 8: 223–230
- Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol 2007; 138: 202–212
- Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res 2005; 11: 7297–7303